Cancer Research UK

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Multi-cancer early detection tests: a simple blood test has the potential to revolutionise cancer screening

Retrieved on: 
Monday, February 5, 2024

Swiss Re Institute's new report "Multi-Cancer Early Detection: cancer screening beyond today's boundaries", explores the future risks and opportunities for patients and insurers.

Key Points: 
  • Swiss Re Institute's new report "Multi-Cancer Early Detection: cancer screening beyond today's boundaries", explores the future risks and opportunities for patients and insurers.
  • However, given this early stage of their development, we need to carefully examine their potential, their risks, and the implications for insurers."
  • MCED blood tests are a type of liquid biopsy which can detect cancer biomarkers in a single sample of blood.
  • How to order this study:
    You can download "Multi-Cancer Early Detection: cancer screening beyond today's boundaries" here .

Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023

Retrieved on: 
Friday, November 10, 2023

Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023.
  • Lean, go-to-market commercial model, well positioned to scale rapidly to generate significant value from Japan and APAC (ex-China) geographic expansion.
  • Note regarding the Idorsia transaction: the quarter ended 30 September 2023 (Q3 2023) is the first period in which the Group has consolidated the financial results of Idorsia’s former Japanese and South Korean businesses.
  • Revenue totalled JPY 5,474 million (US$39.6 million*), a decrease of JPY 3,167 million (US$27.9 million) vs. the prior corresponding period.

Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities

Retrieved on: 
Monday, December 4, 2023

Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment.

Key Points: 
  • Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment.
  • The agreement will enable the parties to discuss opportunities for collaboration to support the charity’s research and clinical development activities, focusing primarily on its clinical trials run by its Centre for Drug Development.
  • This includes the DETERMINE trial – the first UK national precision medicine trial in rare cancers, and other Cancer Research UK and Cancer Research Horizons research collaborations.
  • Additional potential collaboration activities may include sharing data and samples from the Cancer Research UK-funded research network to further develop and validate Guardant’s technologies, as well as explore other projects to accelerate the discovery and development of cancer drugs and diagnostics.

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

Retrieved on: 
Monday, December 4, 2023

NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.

Key Points: 
  • NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.
  • This published report informs UK doctors, patients, and other interested parties that NICE has started the review of Multikine and is soliciting public comment.
  • The NICE briefing includes the following statements:
    “The current standard of care for locally advanced SCCHN is an aggressive combined modality therapy.
  • According to Cancer Research UK , an average of 12,400 cases of head and neck cancer are diagnosed each year in the UK.

Genialis and Cancer Research Horizons Collaborate to Develop AI-Driven Patient Classifiers

Retrieved on: 
Monday, October 23, 2023

Genialis , the RNA-biomarker company, today announced a new data-sharing collaboration with Cancer Research Horizons (CRH), the innovation arm of Cancer Research UK.

Key Points: 
  • Genialis , the RNA-biomarker company, today announced a new data-sharing collaboration with Cancer Research Horizons (CRH), the innovation arm of Cancer Research UK.
  • Under the terms of the collaboration, CRH will make anonymized and curated datasets with 'omics and clinical metadata available to Genialis to validate Genialis ResponderID™ technology and machine learning-derived patient classifiers.
  • Collaboration is key to expediting the development of clinically actionable biomarkers for better patient selection so that the right drug reaches the right patient at the right time.
  • “Cancer Research UK’s research network is generating huge amounts of detailed, highly curated data that can be used to support the development of tools and products that can benefit patients.

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Retrieved on: 
Monday, October 23, 2023

The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.

Key Points: 
  • The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
  • As of the data cut-off on 8 September 2023, the trial had enrolled 23 heavily pre-treated patients across various tumor types where HER3 may play an important role.
  • The dose escalation trial cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs) and there were no treatment discontinuations due to related adverse events.
  • " The Phase I/IIa clinical trial in the UK is sponsored and managed by Cancer Research UK's Centre for Drug Development.

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Retrieved on: 
Monday, October 23, 2023

The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.

Key Points: 
  • The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
  • As of the data cut-off on 8 September 2023, the trial had enrolled 23 heavily pre-treated patients across various tumor types where HER3 may play an important role.
  • The dose escalation trial cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs) and there were no treatment discontinuations due to related adverse events.
  • " The Phase I/IIa clinical trial in the UK is sponsored and managed by Cancer Research UK's Centre for Drug Development.

Parker Moss to Join Exscientia as EVP, Corporate Development

Retrieved on: 
Tuesday, October 17, 2023

Exscientia plc (Nasdaq: EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024.
  • In this newly established role, Parker will lead the creation and execution of a focused corporate development strategy to strengthen further and create new market opportunities for the company’s precision medicine, clinical and tech innovation platforms, with a particular focus on oncology.
  • Parker is also the co-lead of Genomics England’s research programme in cancer and rare disease.
  • Parker also holds several non-executive roles, including on the Cancer Research Horizons board (a company wholly owned by Cancer Research UK).

 Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer

Retrieved on: 
Tuesday, October 3, 2023

In the two dose schedules with administration pre-CRT and post-CRT, mrTRG of 1 or 2 was observed in 5 out of 10 (50%) of the treated patients.

Key Points: 
  • In the two dose schedules with administration pre-CRT and post-CRT, mrTRG of 1 or 2 was observed in 5 out of 10 (50%) of the treated patients.
  • Further, hexon staining of patient samples suggested EnAd localization in both the primary tumor and in metastatic sites.
  • “These data are compelling given the higher-than-expected pCR/cCR rate, and the low adverse event rate highlights the ability to deliver the oncolytic virus concurrently with chemoradiation.
  • ET
    Presenter: Dr Séan M. O’Cathail, MSc DPhil MRCPI FRCP FRCR, Senior Research Fellow, School of Cancer Sciences, University of Glasgow